clinical trial · NCT05065970
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
HI-Bio, A Biogen Company·phase2·completed·n = 54
Immunoglobulin A (IgA) NephropathyFelzartamabPlacebo
brief summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
started
Aug 31, 2021
primary completion
Feb 6, 2023
completion
May 6, 2024
last updated
Feb 7, 2025
detailed description
Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.
official title
A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol